Exanthema Market Report 2026

The exanthema market size has grown steadily in recent years. It will grow from $2.26 billion in 2025 to $2.35 billion in 2026 at a compound annual growth rate (CAGR) of 4.1%. The growth in the historic period can be attributed to viral infection outbreaks, childhood disease prevalence, clinical diagnosis reliance, vaccination gaps, dermatology consultation growth.

The exanthema market size is expected to see steady growth in the next few years. It will grow to $2.76 billion in 2030 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to improved diagnostic awareness, viral surveillance programs, pediatric healthcare expansion, early intervention protocols, infection control initiatives. Major trends in the forecast period include rising incidence of viral skin infections, increased focus on early clinical diagnosis, expansion of supportive care treatments, growth in pediatric rash management, emphasis on infection-specific treatment.

The rising prevalence of viral infections is expected to drive the growth of the exanthema market going forward. Viral infections are illnesses caused by viruses that invade and multiply within the body’s cells, resulting in various symptoms and diseases. Factors such as increased global travel, urbanization, climate change, and weakened immunity have contributed to the rise in viral infections. As viral infections increase, the demand for exanthema treatments also grows, since more cases present with skin rashes, highlighting the need for effective management. Exanthema represents a visible immune response to viral infections, helping eliminate pathogens, signal immune activation, and assist in diagnosis by indicating the body’s defense against the virus. For instance, in August 2024, the Centers for Disease Control and Prevention, a US-based government agency, reported that the proportion of individuals with IgM antibodies, indicating recent Parvovirus B19 infection, remained below 3% in 2022-2024 but surged to 10% by June 2024. The most significant increase was observed in children aged 5-9 years, rising from 15% to 40% during this period. Therefore, the rising prevalence of viral infections is driving the exanthema market.

Major companies in the exanthema market are focusing on novel therapeutics, such as intramuscular (IM) administration of vaccines and antiviral treatments, to improve efficacy, reduce complications, and enhance patient outcomes in managing viral infections linked to exanthematous diseases. Intramuscular (IM) administration involves delivering medications or vaccines directly into muscle tissue using a syringe and needle. This method allows rapid absorption into the bloodstream, utilizing the rich blood supply in muscles to trigger an immune response or therapeutic effect. For instance, in March 2023, Merck & Co. Inc., a US-based pharmaceutical company, announced that the FDA approved intramuscular (IM) administration for its MMRV vaccines - M-M-R II, VARIVAX, and ProQuad. The IM route offers greater stability and efficacy for these live-virus vaccines compared to other administration methods, supporting public health efforts in preventing potentially severe viral infections.

In September 2024, Organon, a US-based healthcare company, acquired Dermavant Sciences Ltd. for $1.2 billion. This acquisition strengthens Organon’s dermatology portfolio, enhances its offerings with innovative therapies, and aligns with its strategic goals. Dermavant Sciences Ltd. is a US-based clinical-stage biopharmaceutical company focused on developing innovative therapeutics in immunodermatology.

Major companies operating in the exanthema market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi SA, Abbott Laboratories, GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Company Limited, Amgen Inc., Daiichi Sankyo Company Limited, Biological E. Limited, Zydus Lifesciences Limited, Bio Farma, Meridian Bioscience Inc., West-Ward Pharmaceutical Corp., Trinity Biotech plc, Biosynth Srl, Creative Diagnostics, Taj Pharmaceuticals Limited, TestLine Clinical Diagnostics s.r.o., The Native Antigen Co. Ltd., QED Bioscience Inc.

North America was the largest region in the exanthema market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the exanthema market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the exanthema market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the exanthema market by increasing costs of imported diagnostic kits, antiviral medications, and supportive care products. Hospitals and specialty centers in developed regions are most affected due to reliance on imported medical supplies. These tariffs raise treatment costs by increasing diagnostic and therapeutic expenses for viral and immune-related skin conditions. However, they support domestic pharmaceutical production, strengthening regional supply chains for antiviral and supportive therapies.

The exanthema market research report is one of a series of new reports that provides exanthema market statistics, including exanthema industry global market size, regional shares, competitors with a exanthema market share, detailed exanthema market segments, market trends and opportunities, and any further data you may need to thrive in the exanthema industry. This exanthema market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Exanthema refers to a widespread rash or skin eruption, typically caused by viral infections such as measles, rubella, or varicella (chickenpox). It is used to help diagnose and identify viral diseases, as the characteristics of the rash often assist healthcare providers in determining the underlying infection and guiding appropriate treatment and management.

The main types of exanthema include bacterial, viral, and others. Bacterial exanthema is caused by bacterial infections, presenting as skin rashes due to pathogens such as Streptococcus or Staphylococcus species. Treatments include topical therapies, systemic treatments, and supportive care. Diagnostic approaches may involve clinical examination, laboratory tests, and imaging techniques. Applications of exanthema assessment include conditions such as rubeola, rubella, erythema infectiosum, and roseola infantum. These services and treatments are used by various end users, including hospitals, homecare providers, specialty centers, and others.

The exanthema market consists of revenues earned by entities by providing services such as antiviral treatment services, vaccination services, and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The exanthema market also includes sales of topical corticosteroids, antihistamines, immunosuppressants, antiviral medications, and moisturizers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.